Accredo
Privacy |  HIPAA |  Terms of use |  Medco |  Contact us
   
Patients Healthcare professionals Health plans & payor clients Manufacturers Careers About Accredo
 
 
 

Patients

Getting started with Accredo
Our services
Search drug therapies
Therapy management
Disposal of unused meds
Naglazyme® (galsulfase) - product information

Naglazyme® (galsulfase)

Overview | Product information | Accredo services | Contact team


MPS VI (mucopolysaccharidosis VI), also known as Maroteaux-Lamy syndrome, is an inherited metabolic disorder caused by the deficiency of N-acetylgalactosamine 4-sulfatase (arylsulfatase B), an enzyme normally required for the breakdown of certain complex carbohydrates known as glycosaminoglycans (GAG). If the enzyme is not present in sufficient quantities, the normal breakdown of GAG is incomplete or blocked. The cell is unable to excrete the carbohydrate residues, which then accumulate in the lysosomes of the cell. This accumulation disrupts the cell's normal functioning and gives rise to the physical manifestations of the disease.

MPS VI affects males and females equally, and in most cases, both parents of an affected child are asymptomatic carriers of the disease. MPS VI is a disease with a wide variation in the rate of disease progression, the severity of symptoms, and the organ systems affected. Unlike MPS I, MPS VI does not typically affect cognitive function.


Naglazyme is a trademark of BioMarin Pharmaceutical Inc.

 
 
 

Quick links

Search Search drug therapies
Doctor Referral Doctor referral forms
Patient Authorization Patient authorization form
Contact Us Contact us